{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:37:28Z","timestamp":1785515848647,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003594.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000}}],"reference-count":155,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003594.pub6","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T06:07:34Z","timestamp":1574316454000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Interventions for idiopathic steroid-resistant nephrotic syndrome in children"],"prefix":"10.1002","author":[{"given":"Isaac D","family":"Liu","sequence":"first","affiliation":[{"name":"National University Health System; Department of Paediatrics; 1E Kent Ridge Road, NUHS Tower Block, Level 12 Singapore Singapore 119228"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narelle S","family":"Willis","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"},{"name":"Flinders University; College of Medicine and Public Health; Adelaide SA Australia 5001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M","family":"Hodson","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD003594.pub6-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00467-008-0794-1","article-title":"Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft fur Padiatrische Nephrologie","volume":"23","author":"Plank","year":"2008","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00467-003-1314-y","article-title":"Enalapril dosage in steroid-resistant nephrotic syndrome","volume":"19","author":"Bagga","year":"2004","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0003|cit3","unstructured":"Bagga A Mudigoudar BD Vasudev V Hari P Low (LD) versus high dose (HD) enalapril therapy in steroid resistant nephrotic syndrome (SRNS) [abstract] 7th Asian Congress of Pediatric Nephrology; 2000 Nov 4-6; Singapore 2000"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub6-BIB0004|cit4","first-page":"190","article-title":"Comparison of pulse methyl prednisolone vs cyclosporin based therapy in steroid resistant focal segmental glomerulosclerosis [abstract]","volume":"12","author":"Bhaumik","year":"2002","journal-title":"Indian Journal of Nephrology"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0005|cit5","first-page":"S122","article-title":"Effects of tuna fish oil on hyperlipidemia and proteinuria in childhood nephrotic syndrome","volume":"82 Suppl 1","author":"Chongviriyaphan","year":"1999","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub6-BIB0006|cit6","first-page":"1480","article-title":"Randomized controlled trial (RCT) on efficacy and safety of cyclosporin (CyA) vs tacrolimus (Tac) in steroid resistant nephrotic syndrome (SRNS) [CRG030600042] [abstract no: 182 (OP)]","volume":"22","author":"Choudhry","year":"2007","journal-title":"Pediatric Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub6-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1053\/j.ajkd.2008.11.033","article-title":"Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial","volume":"53","author":"Choudhry","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003594.pub6-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"iii97","DOI":"10.1093\/ndt\/gfx134.TO042","article-title":"Antiproteinuric effect of sparsentan, a dual angiotensin II and endothelin type A receptor antagonist, in patients with primary focal segmental glomerulosclerosis (FSGS): a subgroup analysis of the DUET trial [abstract no: TO042]","volume":"32","author":"Gesualdo","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts Suppl","key":"10.1002\/14651858.CD003594.pub6-BIB0009|cit9","first-page":"61","article-title":"Long-term effects of sparsentan, a dual angiotensin and endothelin receptor antagonist in primary focal segmental glomerulosclerosis (FSGS): interim 84-week analysis of the DUET trial [abstract no: FR-OR087]","volume":"29","author":"Hogan","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub6-BIB0010|cit10","first-page":"843","article-title":"Sparsentan pharmacokinetics and pharmacodynamics as the basis of dose selection for primary focal segmental glomerular sclerosis (FSGS) [abstract no: SA-PO635]","volume":"28","author":"Karol","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub6-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ekir.2017.02.019","article-title":"Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET)","volume":"2","author":"Komers","year":"2017","journal-title":"Kidney International Reports"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD003594.pub6-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.ekir.2019.05.432","article-title":"No impact of newly initiated immunosuppressive therapy observed on long-term antiproteinuric effect of sparsentan in focal segmental glomerulosclerosis: interim 84-week analysis of the DUET trial [abstract no: SUN-037]","volume":"4","author":"Tesar","year":"2019","journal-title":"Kidney International Reports"},{"issue":"11","key":"10.1002\/14651858.CD003594.pub6-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS","volume":"29","author":"Trachtman","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub6-BIB0014|cit14","first-page":"2B","article-title":"Efficacy and safety of sparsentan, a dual angiotensin II (Ang II) and endothelin (ET) type A receptor antagonist in patients with focal segmental glomerulosclerosis (FSGS): a phase 2 trial (DUET) [abstract no: HI-OR06]","volume":"27","author":"Trachtman","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003594.pub6-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/ndt\/gfy104.FP129","article-title":"Newly administered immunosuppressive therapy (IST) has no impact on long-term antiproteinuric effect of sparsentan (SPAR), a dual angiotensin and endothelin receptor antagonist, in patients with primary focal segmental glomerulosclerosis (FSGS): interim analysis of the DUET trial [abstract no: FP129]","volume":"33","author":"Trachtman","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub6-BIB0016|cit16","first-page":"44","article-title":"Long-term effect of sparsentan (SPAR), a dual angiotensin and endothelin receptor antagonist, on proteinuria in patients with primary FSGS: interim analysis of the DUET trial [abstract no: FR-OR026]","volume":"28","author":"Trachtman","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00868243","article-title":"Intravenous pulse cyclophosphamide - a new regime for steroid-resistant minimal change nephrotic syndrome","volume":"8","author":"Elhence","year":"1994","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0018|cit18","unstructured":"Gupta A Elhence R Kher V Gulati S Sharma RK IV cyclophosphamide - a new regimen for steroid nonresponsive minimal change disease [abstract] 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel 1993 84"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub6-BIB0019|cit19","first-page":"382","article-title":"Implementing a second randomized trial enrolling mid-study treatment failures from the Focal Segmental Glomerular Sclerosis (FSGS) clinical trial [abstract no: 33]","volume":"4","author":"Gassman","year":"2007","journal-title":"Clinical Trials (London, England)"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2215\/CJN.02310508","article-title":"Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group","volume":"4","author":"Joy","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.ajkd.2009.08.019","article-title":"Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group","volume":"55","author":"Joy","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub6-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-015-1973-1","article-title":"A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS)","volume":"72","author":"Ternant","year":"2016","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub6-BIB0023|cit23","first-page":"1629","article-title":"Novel therapies in resistant FSGS: preliminary results [abstract no: 879 (P)]","volume":"22","author":"Trachtman","year":"2007","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2369-12-8","article-title":"Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design","volume":"12","author":"Trachtman","year":"2011","journal-title":"BMC Nephrology"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12882-015-0094-5","article-title":"Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the FONT clinical trial group","volume":"16","author":"Trachtman","year":"2015","journal-title":"BMC Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub6-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2215\/CJN.06100612","article-title":"Association of histologic variants in FSGS clinical trial with presenting features and outcomes","volume":"8","author":"D'Agati","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/cts.12003","article-title":"Patient recruitment into a multicenter randomized clinical trial for kidney disease: report of the focal segmental glomerulosclerosis clinical trial (FSGS CT)","volume":"6","author":"Ferris","year":"2013","journal-title":"Clinical & Translational Science"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003594.pub6-BIB0028|cit28","first-page":"559A","article-title":"A preliminary report of the focal segmental glomerulosclerosis clinical trial (FSGS-CT) [abstract no: F-PO1984]","volume":"19","author":"Gassman","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub6-BIB0029|cit29","first-page":"382","article-title":"Implementing a second randomized trial enrolling mid-study treatment failures from the Focal Segmental Glomerular Sclerosis (FSGS) Clinical Trial [abstract no: 33]","volume":"4","author":"Gassman","year":"2007","journal-title":"Clinical Trials"},{"issue":"Abstracts issue","key":"10.1002\/14651858.CD003594.pub6-BIB0030|cit30","first-page":"147","article-title":"Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) study cohort [abstract no: TH-PO165]","volume":"20","author":"Gipson","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub6-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub6-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ki.2010.485","article-title":"Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life","volume":"79","author":"Gipson","year":"2011","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0033|cit33","first-page":"558A","article-title":"Multicenter randomized clinical trial of FSGS in children and young adults [abstract no: F-PO1014]","volume":"16","author":"Greene","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub6-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2215\/CJN.08330812","article-title":"Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS","volume":"8","author":"Hogg","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub6-BIB0035|cit35","first-page":"1443","article-title":"Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS Clinical Trial","volume":"26","author":"Kopp","year":"2015","journal-title":"Journal of the American Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub6-BIB0036|cit36","first-page":"41A","article-title":"APOL1 variant-associated FSGS is more aggressive but manifests similar response to cyclosporine and mycophenolate compared to others forms of primary FSGS [abstract no: FR-OR050]","volume":"23","author":"Kopp","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts issue","key":"10.1002\/14651858.CD003594.pub6-BIB0037|cit37","first-page":"148A","article-title":"Prevalence of blood pressure (BP) control in the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) study cohort [abstract]","volume":"20","author":"Middleton","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub6-BIB0038|cit38","first-page":"417","article-title":"Optimizing logistics under a three level administration system: coordination of the Focal Segmental Glomerular Sclerosis (FSGS) trial [abstract no: P63]","volume":"4","author":"Radeva","year":"2007","journal-title":"Clinical Trials (London, England)"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub6-BIB0039|cit39","first-page":"471","article-title":"Measuring quality of life (QOL) in children and young adults in the focal segmental glomerulosclerosis clinical trial (FSGS-CT) [abstract]","volume":"7","author":"Radeva","year":"2010","journal-title":"Clinical Trials"},{"issue":"11","key":"10.1002\/14651858.CD003594.pub6-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00467-015-3146-y","article-title":"Adiponectin in children and young adults with focal segmental glomerulosclerosis","volume":"30","author":"Sethna","year":"2015","journal-title":"Pediatric Nephrology"},{"issue":"Abstracts issue","key":"10.1002\/14651858.CD003594.pub6-BIB0041|cit41","first-page":"147A","article-title":"Quality of life in children with focal segmental glomerulosclerosis (FSGS): baseline findings. Report of the FSGS-Clinical Trial (CT) [abstract no: TH-PO164]","volume":"20","author":"Trachtman","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub6-BIB0042|cit42","first-page":"727A","article-title":"Osteopontin (OPN) and transforming growth factor beta 1 (TGFb1) in steroid resistant primary focal segmental glomerulosclerosis (FSGS), FSGS-clinical trial (FSGS-CT) experience [abstract no: SA-PO390]","volume":"23","author":"Woroniecki","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub6-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archpedi.1988.02150090083029","article-title":"Cyclosporine therapy for steroid-resistant nephrotic syndrome. A controlled study","volume":"142","author":"Garin","year":"1988","journal-title":"American Journal of Diseases of Children"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003594.pub6-BIB0044|cit44","first-page":"1B","article-title":"Multicenter randomized controlled trial comparing efficacy of tacrolimus to intravenous cyclophosphamide in children with steroid resistant nephrotic syndrome [abstract no: LB-OR03]","volume":"22","author":"Gulati","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub6-BIB0045|cit45","first-page":"1803","article-title":"Randomized, multicenter study on tacrolimus & alternate day (AD) prednisolone vs. intravenous (IV) cyclophosphamide & ad prednisolone for steroid resistant nephrotic syndrome (SRNS) [abstract no: 43]","volume":"25","author":"Gulati","year":"2010","journal-title":"Pediatric Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub6-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.2012.238","article-title":"Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome","volume":"82","author":"Gulati","year":"2012","journal-title":"Kidney International"},{"issue":"7654","key":"10.1002\/14651858.CD003594.pub6-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(70)91093-7","article-title":"Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children","volume":"1","author":"Abramowicz","year":"1970","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0048|cit48","first-page":"95","article-title":"International trial of azathioprine in nephrotic syndrome in childhood [abstract]","volume":"8","author":"Arneil","year":"1971","journal-title":"Nephron"},{"issue":"7878","key":"10.1002\/14651858.CD003594.pub6-BIB0049|cit49","first-page":"423","article-title":"Prospective, controlled trial of cyclophosphamide therapy in children with the nephrotic syndrome. Report of the International Study of Kidney Disease in Children","volume":"2","year":"1974","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub6-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s004670050167","article-title":"Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children","volume":"10","author":"Tarshish","year":"1996","journal-title":"Pediatric Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD003594.pub6-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM198003203021214","article-title":"Irreversible renal failure after indomethacin in steroid-resistant nephrosis","volume":"302","author":"Kleinknecht","year":"1980","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0052|cit52","first-page":"96","article-title":"Irreversible renal failure (RF) after indomethacin in steroid resistant nephrosis (SRN) [abstract]","volume":"16","author":"Kleinknecht","year":"1979","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1681\/ASN.V7156","article-title":"A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children","volume":"7","author":"Lieberman","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003594.pub6-BIB0054|cit54","first-page":"289","article-title":"A randomized placebo (PL) controlled double blind trial of cyclosporine (CSA) in steroid resistant (SR) idiopathic focal segmental glomerulosclerosis (FSGS) in children. A report of the New York, New Jersey Pediatric Nephrology Collaborative Study Group [abstract]","volume":"4","author":"Tejani","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub6-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1681\/ASN.2011080775","article-title":"Rituximab in children with resistant idiopathic nephrotic syndrome","volume":"23","author":"Magnasco","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub6-BIB0056|cit56","first-page":"C73","article-title":"Efficacy of IV pulse cyclophosphamide (CP) vs IV steroids and oral CP for steroid resistant nephrotic syndrome [abstract no: OFC44]","volume":"19","author":"Mantan","year":"2004","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub6-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00467-008-0860-8","article-title":"Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome","volume":"23","author":"Mantan","year":"2008","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub6-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/ki.1993.194","article-title":"A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome","volume":"43","author":"Ponticelli","year":"1993","journal-title":"Kidney International"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub6-BIB0059|cit59","first-page":"1879","article-title":"Randomized controlled trial of oral versus intravenous cyclophosphamide in idiopathic steroid resistant nephrotic syndrome [abstract no: 424]","volume":"25","author":"Ohri","year":"2010","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub6-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4103\/ijn.IJN_201_16","article-title":"A randomized controlled trial of intravenous versus oral cyclophosphamide in steroid-resistant nephrotic syndrome in children","volume":"27","author":"Shah","year":"2017","journal-title":"Indian Journal of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub6-BIB0061|cit61","first-page":"1600","article-title":"Randomized controlled trial comparing efficacy of mycophenolate mofetil (MMF) & alternate day prednisone versus tacrolimus & prednisolone in maintaining remission in steroid resistant nephrotic syndrome (SRNS) [abstract no: P-SUN200]","volume":"28","author":"Bagga","year":"2013","journal-title":"Pediatric Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub6-BIB0062|cit62","first-page":"B2","article-title":"Randomized trial on efficacy of mycophenolate mofetil versus tacrolimus in maintaining remission in children in steroid resistant nephrotic syndrome [abstract no: HI-OR05]","volume":"26","author":"Sinha","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2017.01.019","article-title":"Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome","volume":"92","author":"Sinha","year":"2017","journal-title":"Kidney International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub6-BIB0064|cit64","first-page":"774A","article-title":"Superior results with tacrolimus than ciclosporine in children with steroid resistant nephrotic syndrome [abstract no: SA-PO2854]","volume":"22","author":"Medeiros","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub6-BIB0065|cit65","first-page":"1804","article-title":"Efficacy of prednisone-tacrolimus vs. prednisone-cyclosporine in steroid-resistant nephrotic syndrome [abstract no: 47]","volume":"25","author":"Valverde","year":"2010","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nep.12351","article-title":"Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing","volume":"20","author":"Wu","year":"2015","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0067|cit67","unstructured":"Li ZH Yi ZW Clinical study of fosinopril in children with steroid resistant nephrotic syndrome [abstract no: 2344] 23rd International Congress of Paediatrics; 2001 Sep 9-14; Beijing, China 2001"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub6-BIB0068|cit68","first-page":"C114","article-title":"Clinical study of fosinopril in children with steroid resistant nephrotic syndrome [abstract no: P225]","volume":"16","author":"Li","year":"2001","journal-title":"Pediatric Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003594.pub6-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00467-006-0096-4","article-title":"Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome","volume":"21","author":"Yi","year":"2006","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub6-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/adc.54.3.204","article-title":"A controlled trial of cyclophosphamide and azathioprine in Nigerian children with the nephrotic syndrome and poorly selective proteinuria","volume":"54","author":"Adeniyi","year":"1979","journal-title":"Archives of Disease in Childhood"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub6-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.krcp.2014.05.017","article-title":"Efficacy and safety of rituximab in children with refractory nephrotic syndrome: a multicenter clinical trial [abstract]","volume":"33","author":"Ahn","year":"2014","journal-title":"Kidney Research & Clinical Practice"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub6-BIB0072|cit72","first-page":"1361","article-title":"Efficacy and safety of rituximab in children with refractory nephrotic syndrome: a multicenter clinical trial [abstract no: 039]","volume":"28","author":"Ahn","year":"2013","journal-title":"Pediatric Nephrology"},{"issue":"46","key":"10.1002\/14651858.CD003594.pub6-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","article-title":"Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea","volume":"97","author":"Ahn","year":"2018","journal-title":"Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub6-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0971-4065.34855","article-title":"Randomised controlled study of enalapril in steroid resistant nephrotic syndrome","volume":"12","author":"Arora","year":"2002","journal-title":"Indian Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0075|cit75","first-page":"40","article-title":"The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome","volume":"44","author":"Buyukcelik","year":"2002","journal-title":"Turkish Journal of Pediatrics"},{"issue":"12","key":"10.1002\/14651858.CD003594.pub6-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00467-018-4036-x","article-title":"Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial","volume":"33","author":"Hari","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub6-BIB0077|cit77","first-page":"1737","article-title":"Effect of atorvastatin on lipid profile and carotid intima media thickness (cIMT) in children with refractory nephrotic syndrome: a randomized double blind, placebo controlled trial [abstract no: FP-S14-3]","volume":"31","author":"Hari","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub6-BIB0078|cit78","first-page":"1335","article-title":"Low versus standard dosage of prednisolone for initial treatment of idiopathic nephrotic syndrome in children [abstract no: A0445]","volume":"7","author":"Hiraoka","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub6-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1046\/j.1523-1755.2000.00279.x","article-title":"Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome. The West Japan Cooperative Study of Kidney Disease in Children","volume":"58","author":"Hiraoka","year":"2000","journal-title":"Kidney International"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003594.pub6-BIB0080|cit80","first-page":"103A","article-title":"Older boys benefit from intensive initial prednisolone therapy for nephrotic syndrome [abstract]","volume":"10","author":"Hiraoka","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003594.pub6-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00467-006-0054-1","article-title":"Steroid sparing effect of a herbal preparation in steroid-dependent nephrotic syndrome","volume":"21","author":"Iyengar","year":"2006","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0082|cit82","unstructured":"Ito S A combination of cyclosporine and prednisolone and a combination of methylprednisolone, cyclosporine and prednisolone for steroid-resistant nephrotic syndrome in children: A randomized controlled study https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000000010"},{"issue":"2 Pt II","key":"10.1002\/14651858.CD003594.pub6-BIB0083|cit83","first-page":"A 33","article-title":"Immunomodulatory treatment in children with steroid-dependent\/steroid-resistant nephrotic syndrome [abstract no: 170]","volume":"20","author":"Jung","year":"1990","journal-title":"European Journal of Clinical Investigation"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub6-BIB0085|cit84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5414\/CNP60085","article-title":"Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria","volume":"60","author":"Kano","year":"2003","journal-title":"Clinical Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003594.pub6-BIB0084|cit85","first-page":"524","article-title":"Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria [abstract no: T756-757]","volume":"18","author":"Kano","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003594.pub6-BIB0086|cit86","first-page":"A33","article-title":"Effect of fluvastatin on proteinuria [abstract no: M-PO20068]","volume":"10","author":"Kano","year":"2005","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub6-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5414\/CNP63074","article-title":"No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria","volume":"63","author":"Kano","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub6-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"57","DOI":"10.22442\/jlumhs.161520465","article-title":"Cyclosporine versus cyclophosphamide in childhood nephrotic syndrome","volume":"15","author":"Khemani","year":"2016","journal-title":"Journal of the Liaquat University of Medical & Health Sciences"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0089|cit89","first-page":"631","article-title":"Clinical evaluation of an immunosuppressive drug, mizoribine (HE-69) on steroid resistant nephrotic syndrome - a multicenter double-blind comparison study with placebo","volume":"34","author":"Koshikawa","year":"1993","journal-title":"Jin to Toseki [Kidney and Dialysis]"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub6-BIB0090|cit90","first-page":"110","article-title":"Effect of ACE inhibitor and calcium channel blocker on proteinuria in subjects with steroid resistant idiopathic nephrotic syndrome [abstract no: CNO-20]","volume":"11","author":"Kumar","year":"2001","journal-title":"Indian Journal of Nephrology"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0091|cit91","first-page":"454","article-title":"Comparative study of angiotensin converting enzyme inhibitor and calcium channel blocker in the treatment of steroid-resistant idiopathic nephrotic syndrome","volume":"52","author":"Kumar","year":"2004","journal-title":"Journal of the Association of Physicians of India"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003594.pub6-BIB0092|cit92","first-page":"569A","article-title":"Therapy of tacrolimus in steroid-resistant minimal-change nephrotic syndrome: a randomized controlled clinical trial [abstract no: F-PO1105]","volume":"17","author":"Li","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD003594.pub6-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3724\/SP.J.1008.2011.01340","article-title":"Low-dose tacrolimus combined with tripterygium in treatment of steroid-resistant nephrotic syndrome: a prospective randomized controlled trial","volume":"32","author":"Ren","year":"2011","journal-title":"Academic Journal of Second Military Medical University"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000346256","article-title":"Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial","volume":"37","author":"Ren","year":"2013","journal-title":"American Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub6-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s10157-013-0925-2","article-title":"Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial","volume":"18","author":"Saito","year":"2014","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003594.pub6-BIB0096|cit96","first-page":"562A","article-title":"Effect of preprandial once-a-day administration of cyclosporine (CyA) for steroid resistant nephrotic syndrome (SRNS) [abstract no: SA-PO997]","volume":"18","author":"Saito","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003594.pub6-BIB0097|cit97","first-page":"634A","article-title":"Benefits of once-a-day preprandial administration and C2 monitoring for the cyclosporine (CyA) treatment of idiopathic membranous nephropathy (IMN) with steroid resistant nephrotic syndrome (SRNS) [abstract no: SA-PO2293]","volume":"20","author":"Saito","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0098|cit98","unstructured":"Saito T Watanabe M Ogahara S Shuto H Kataoka Y Significance of blood concentration of cyclosporine at 2 hours after administration for the treatment of idiopathic membranous nephropathy with steroid resistant nephrotic syndrome [abstract no: SA285] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub6-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10157-016-1340-2","article-title":"Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome","volume":"21","author":"Saito","year":"2017","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003594.pub6-BIB0100|cit100","first-page":"iii430","article-title":"Effects of mizoribin combined with prednisolone for the treatment of idiopathic membranous nephropathy with steroid resistant nephrotic syndrome [abstract no: Su363]","volume":"3","author":"Saito","year":"2010","journal-title":"NDT Plus"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub6-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10157-004-0276-0","article-title":"A randomized open-label comparative study of conventional therapy versus mizoribine only therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey)","volume":"8","author":"Shibasaki","year":"2004","journal-title":"Clinical & Experimental Nephrology"},{"issue":"3 Suppl 4","key":"10.1002\/14651858.CD003594.pub6-BIB0102|cit102","first-page":"262","article-title":"A randomized trial of cyclosporine with low-dose prednisone compared with high-dose prednisone in nephrotic syndrome","volume":"20","author":"Tejani","year":"1988","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000186526","article-title":"A randomized controlled trial of low-dose prednisone and ciclosporin versus high-dose prednisone in nephrotic syndrome of children","volume":"59","author":"Tejani","year":"1991","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0104|cit104","first-page":"213","article-title":"Randomized trial of cylosporine and low dose prednisone (P&CS) vs conventional prednisone (P) therapy in recent onset (< 1 yr) nephrotic syndrome (NS) [abstract]","volume":"35","author":"Tejani","year":"1989","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub6-BIB0105|cit105","first-page":"1162","article-title":"Cyclosporin a (Cy-A) treatment in focal and segmental hyalinosis and sclerosis (FSHS): a controlled trial [abstract no: 17]","volume":"36","author":"Walker","year":"1989","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub6-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000185830","article-title":"The effect of treatment of corticosteroid-resistant idiopathic (primary) focal and segmental hyalinosis and sclerosis (focal glomerulosclerosis) with ciclosporin","volume":"54","author":"Walker","year":"1990","journal-title":"Nephron"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub6-BIB0107|cit107","first-page":"575","article-title":"A prospective multicenter clinical control trial on treatment of refractory nephrotic syndrome with mycophenolate mofetil in children","volume":"10","author":"Yi","year":"2008","journal-title":"Zhongguo Dangdai Erke Zazhi"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub6-BIB0108|cit108","first-page":"1601","article-title":"Treatment with tacrolimus and prednisone is preferable to intravenous cyclophosphamide for children with difficult-to-treat nephrotic syndrome [abstract no: P-SUN205]","volume":"28","author":"Zhao","year":"2013","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0109|cit109","unstructured":"Komers R Study of sparsentan in patients with primary focal segmental glomerulosclerosis (FSGS) (DUPLEX) www.clinicaltrials.gov\/ct2\/show\/NCT03493685"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0110|cit110","unstructured":"Basu B Efficacy and safety of rituximab to that of calcineurin inhibitors in children with steroid resistant nephrotic syndrome www.clinicaltrials.gov\/ct2\/show\/NCT02382575 2015"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0111|cit111","unstructured":"Ghiggeri GM Ofatumumab in children with drug resistant idiopathic nephrotic syndrome www.clinicaltrials.gov\/ct2\/show\/NCT02394106 2015"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0112|cit112","article-title":"Availability study of ACTH to treat children SRNS\/SDNS","author":"Li","journal-title":"www.clinicalTrials.gov\/show\/NCT02972346"},{"issue":"1","key":"10.1002\/14651858.CD003594.pub6-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ekir.2017.08.013","article-title":"Randomized clinical trial design to assess abatacept in resistant nephrotic syndrome","volume":"3","author":"Trachtman","year":"2018","journal-title":"Kidney International Reports"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub6-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.kint.2016.10.013","article-title":"Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management","volume":"91","author":"Bierzynska","year":"2017","journal-title":"Kidney International"},{"issue":"11","key":"10.1002\/14651858.CD003594.pub6-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.2215\/CJN.01190210","article-title":"Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome","volume":"5","author":"B\u00fcscher","year":"2010","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fped.2016.00039","article-title":"Ethnic differences in childhood nephrotic syndrome","volume":"4","author":"Chanchlani","year":"2016","journal-title":"Frontiers in Pediatrics"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0117|cit117","first-page":"787","article-title":"Steroid-resistant nephrotic syndrome","volume-title":"Evidence-Based Nephrology","author":"Chua","year":"2009"},{"issue":"21","key":"10.1002\/14651858.CD003594.pub6-BIB0118|cit118","first-page":"1","article-title":"The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review","volume":"11","author":"Colquitt","year":"2007","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub6-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/ki.2011.191","article-title":"Immunosuppressive treatment of focal and segmental glomerulosclerosis: lessons from a randomized controlled trial","volume":"80","author":"Deegens","year":"2011","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub6-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1342-8","DOI":"10.1681\/ASN.2013080852","article-title":"Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence","volume":"25","author":"Ding","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub6-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/ndt\/gfm092","article-title":"Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated","volume":"22","author":"Ehrich","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD003594.pub6-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00467-011-1851-8","article-title":"Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature","volume":"26","author":"Bakkali","year":"2011","journal-title":"Pediatric Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub6-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/ndt\/gfr572","article-title":"Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome","volume":"27","author":"Gellermann","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub6-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00467-005-2097-0","article-title":"Differential risk of remission and ESRD in childhood FSGS","volume":"21","author":"Gipson","year":"2006","journal-title":"Pediatric Nephrology"},{"issue":"7650","key":"10.1002\/14651858.CD003594.pub6-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub6-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7414","key":"10.1002\/14651858.CD003594.pub6-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0128|cit128","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"7211","key":"10.1002\/14651858.CD003594.pub6-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub6-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00467-015-3174-7","article-title":"Long-term outcome of idiopathic steroid-resistant nephrotic syndrome in children","volume":"31","author":"Inaba","year":"2016","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub6-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3476(81)80760-3","article-title":"The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children","volume":"98","year":"1981","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0132|cit132","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","journal-title":"Kidney International Supplements"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub6-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00467-017-3780-7","article-title":"Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options","volume":"33","author":"Kemper","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003594.pub6-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/adc.57.7.544","article-title":"Long-term outcome of primary nephrotic syndrome","volume":"57","author":"Koskimies","year":"1982","journal-title":"Archives of Disease in Childhood"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub6-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00467-012-2304-8","article-title":"Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO","volume":"28","author":"Lombel","year":"2013","journal-title":"Pediatric Nephrology"},{"issue":"9128","key":"10.1002\/14651858.CD003594.pub6-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD003594.pub6-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0022-3476(05)82020-7","article-title":"Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology","volume":"125","author":"Niaudet","year":"1994","journal-title":"Journal of Pediatrics"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub6-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00467-018-3994-3","article-title":"Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings [Erratum in: Pediatr Nephrol. 2019 Mar;34(3):539; PMID: 30443740]","volume":"33","author":"Pelletier","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub6-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.2014050489","article-title":"A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome","volume":"26","author":"Sadowski","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub6-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0141|cit141","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0142|cit142","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub6-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00467-013-2736-9","article-title":"Predictors of remission and relapse in idiopathic nephrotic syndrome: a prospective cohort study","volume":"29","author":"Sureshkumar","year":"2014","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003594.pub6-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1757940","DOI":"10.1155\/2017\/1757940","article-title":"Pulsed vincristine therapy in steroid-resistant nephrotic syndrome","volume":"2017","author":"Thalgahagoda","year":"2017","journal-title":"BioMed Research International"},{"issue":"4","key":"10.1002\/14651858.CD003594.pub6-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2215\/CJN.06260614","article-title":"Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort","volume":"10","author":"Trautmann","year":"2015","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub6-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"3055-65","DOI":"10.1681\/ASN.2016101121","article-title":"Long-term outcome of steroid-resistant nephrotic syndrome in children","volume":"28","author":"Trautmann","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub6-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2215\/CJN.04780517","article-title":"An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis","volume":"13","author":"Troost","year":"2018","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"6","key":"10.1002\/14651858.CD003594.pub6-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s004670050216","article-title":"Steroid-resistant nephrotic focal segmental glomerulosclerosis: a treatable disease","volume":"10","author":"Tune","year":"1996","journal-title":"Pediatric Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003594.pub6-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1440-1754.2007.01077.x","article-title":"Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study","volume":"43","author":"Wong","year":"2007","journal-title":"Journal of Paediatrics & Child Health"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub6-BIB0150|cit150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Habashy","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD003594.pub6-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s00467-003-1207-0","article-title":"Interventions for steroid-resistant nephrotic syndrome: a systematic review","volume":"18","author":"Habashy","year":"2003","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003594.pub6-BIB0152|cit152","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594.pub2","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Habashy","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003594.pub6-BIB0153|cit153","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594.pub3","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Habashy","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD003594.pub6-BIB0154|cit154","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594.pub4","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Hodson","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD003594.pub6-BIB0155|cit155","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594.pub5","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Hodson","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003594.pub7","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003594.pub6\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T12:35:43Z","timestamp":1722083743000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003594.pub6"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":155,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003594.pub6","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]}}}